Hepatocellular Carcinoma Recurrence in HCV Patients Treated with Direct Antiviral Agents

Area of Science:

• Hepatology and Oncology
• Viral Hepatitis Research
• Cancer Recurrence Studies

Background:

• Hepatocellular carcinoma (HCC) recurrence is a significant clinical challenge post-treatment.
• Direct antiviral agents (DAAs) for hepatitis C virus (HCV) were anticipated to reduce HCC recurrence, but their impact remains debated.
• Hundreds of studies have investigated the association between DAAs and HCC development (de novo and recurrence) since 2016.

Purpose of the Study:

• To critically review the impact of DAAs on HCC recurrence.
• To explore potential mechanisms and host factors influencing HCC recurrence after DAA therapy.
• To address methodological challenges in interpreting current research on DAAs and HCC.

Main Methods:

• Systematic literature review and meta-analysis of studies examining DAA treatment and HCC recurrence.
• Analysis of potential biological mechanisms linking DAAs to HCC recurrence.
• Evaluation of methodological factors influencing study outcomes and interpretations.

Main Results:

• The effect of DAAs on HCC recurrence is controversial, with conflicting findings across studies.
• A temporal association between DAA treatment and HCC recurrence has been observed.
• Methodological variations in study designs and patient populations may contribute to disparate results.

Conclusions:

• The role of DAAs in HCC recurrence requires further investigation, considering underlying mechanisms and host factors.
• Current evidence does not definitively support DAAs as a secondary prevention strategy for HCC.
• Revisiting tenets of hepatocarcinogenesis may be necessary, challenging the assumption that HCV elimination alone prevents HCC recurrence.